Fixed Dosing Regimen for HER Antibodies
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments using HER antibodies, such as trastuzumab, often rely on weight-based or body surface area-based dosing methods, which can lead to variability in pharmacokinetics and target drug concentrations, making it challenging to achieve consistent therapeutic effects.
Innovation Solution
Implementing a fixed dosing regimen for HER antibodies like pertuzumab, administered in specific amounts (approximately 420 mg, 525 mg, 840 mg, or 1050 mg) regardless of patient weight or body surface area, to stabilize pharmacokinetics and maintain effective target concentrations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If weight-based or body surface area-based dosing methods are used for HER antibodies, then dosing can be individualized to patient size, but variability in pharmacokinetics and target drug concentrations increases
Solution Approach 1:
The patent changes the dosing parameter from weight-based (mg/kg) or body surface area-based (mg/m²) to a fixed dose (e.g., 420 mg, 525 mg, 840 mg, or 1050 mg). This parameter change eliminates the variability in pharmacokinetics and target drug concentrations that occurs with individualized dosing, while maintaining dosing adaptability through the selection of appropriate fixed dose levels based on patient characteristics and treatment requirements.
2Stability of the object's composition
If fixed dosing is implemented for HER antibodies, then pharmacokinetics stability improves, but dosing flexibility for different patient sizes is reduced
Solution Approach 1:
The patent applies parameter changes by transitioning from continuous dosing adjustments based on patient weight or body surface area to discrete fixed dose levels. This provides pharmacokinetics stability through consistent drug exposure while maintaining dosing flexibility through the availability of multiple fixed dose options (420 mg, 525 mg, 840 mg, 1050 mg) that can be selected based on patient needs.
Solution Approach 2:
The patent segments the dosing regimen into discrete fixed dose levels rather than continuous individualized dosing. This segmentation simplifies the dosing decision-making process and ensures consistent pharmacokinetics within each dose group, while the range of available segmented dose levels provides sufficient flexibility for different patient populations and treatment scenarios.
3Measurement precision
If weight-based dosing is used, then dosing accuracy relative to patient size is improved, but complexity in dosing calculation and administration increases
Solution Approach 1:
The patent extracts the complexity of weight-based calculation from the dosing process by eliminating the need for individualized dose calculations based on patient weight or body surface area. The fixed dosing regimen removes the mathematical calculations and dosing adjustments that clinicians must perform, while maintaining dosing accuracy through clinically validated fixed dose levels that achieve target drug concentrations.
Solution Approach 2:
The patent changes the dosing parameter from a calculated value based on patient measurements to a fixed predetermined value. This parameter change eliminates the complexity of dosing calculations while maintaining dosing accuracy through the selection of fixed dose levels that have been optimized to achieve consistent pharmacokinetic profiles and therapeutic effects across patient populations.
Data Source
AI summary
The present invention concerns fixed dosing of HER antibodies, such as Pertuzumab.